Skip to main content

Thermo Fisher Scientific Value Stock - Dividend - Research Selection

Thermo fisher scientific

ISIN: US8835561023 , WKN: 857209

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. Its Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel products. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Its Laboratory Products and Services segment offers laboratory refrigerators and freezers, ultralow-temperature freezers and cryopreservation storage tanks, temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis and laboratory equipment; laboratory plastics; laboratory chemicals; research and safety market channel; and pharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Thermo Fisher Scientific Inc. (TMO) Carries a Mid-Single Digit Organic Growth Forecast

2026-02-24
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 best life sciences stocks to buy according to hedge funds. On January 30, Daniel Arias of Stifel Nicolaus maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO), with a $700 price target. The analyst reflected on the company’s strong finish to 2025, highlighting that […]

Henry Schein Q4 Earnings Call Highlights

2026-02-24
Henry Schein (NASDAQ:HSIC) reported fourth-quarter 2025 results on Feb. 24, 2026, highlighting what management described as its “highest sales growth in 15 quarters,” alongside progress on its 2025–2027 BOLD+1 strategic plan and an update to its leadership transition. Leadership transition and stra

Cancer Diagnostics Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

2026-02-24
The Cancer Diagnostics Market is set to grow from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, driven by a 7.23% CAGR. Factors like rising cancer incidence, technological advancements in diagnostics, and the importance of early detection are pivotal for this expansion. The market is also fueled by a demand for personalized medicine and enhanced imaging services. Leading companies like Illumina, Abbott Laboratories, and Thermo Fisher Scientific aid this growth through innovations in g

Lung Cancer Diagnostics Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

2026-02-24
The Lung Cancer Diagnostics Market is set to expand from US$ 21.74 billion in 2025 to US$ 38.00 billion by 2033, growing at a CAGR of 7.23%. Major growth drivers include increased public access facilities, rise in ambulance services, and higher prevalence of cardiac disorders. Advances in lung cancer detection techniques like chest X-rays, CT scans, and MRIs cater to the demand for early and accurate diagnoses, crucial for effective treatment. Market leaders such as Illumina, Abbott Laboratories

Thermo Fisher’s Datavant Data Tie-Up Could Be A Game Changer For Thermo Fisher Scientific (TMO)

2026-02-24
Earlier in February 2026, Thermo Fisher Scientific’s PPD clinical research business announced a data collaboration with Datavant to securely connect de-identified real-world patient data across more than 350 data partners and 80,000 U.S. hospitals and clinics into its clinical research, registry and Evidera solutions. This partnership deepens Thermo Fisher’s push into data- and AI-enabled real-world evidence, enhancing its role as an integrated partner for pharma and biotech customers. We’ll...

Harbor Long-Term Growers ETF Q4 2025 Portfolio Performance

2026-02-24

Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference

2026-02-24
WALTHAM, Mass., February 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET).

Next Generation Sequencing Market Competitive Landscape Report 2025 Featuring Top Players - Thermo Fisher Scientific, Pacific Biosciences, Illumina, Roche

2026-02-24
The Next-Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, applications in genomics and personalized medicine, and increased biotech investments. NGS revolutionizes DNA sequencing by rapidly reading millions of genome fragments, enhancing research in genomics, cancer, and infectious diseases. Major players like Illumina, Thermo Fisher Scientific, and

Assisted Reproductive Technology Market Competitive Analysis Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Forecasts to 2033

2026-02-24
The global Assisted Reproductive Technology (ART) market is poised for significant growth, with a value of USD 29.59 billion in 2025, projected to reach USD 49.30 billion by 2033 at a 6.59% CAGR. Key drivers include rising infertility rates, technological advances, and increased awareness of fertility treatments. ART encompasses IVF, ICSI, cryopreservation, and more to aid in conception. Major players like Thermo Fisher, CooperSurgical, and Merck KGaA are propelling innovations and market reach.

Thermo Fisher Scientific (TMO) Valuation Check As Datavant Data Partnership Draws Fresh Investor Interest

2026-02-24
Thermo Fisher Scientific (TMO) is in focus after announcing a data collaboration with Datavant that connects real world data to clinical research, an effort aimed at supporting stronger evidence generation for pharma and biotech clients. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s recent data partnerships and the planned Clario acquisition come as the stock shows mixed momentum, with a 7 day share price return of 2.30% but a 30 day share price return...